Cost-effectiveness of HPV vaccination in Belize

被引:10
|
作者
Walwyn, Leslie [1 ]
Janusz, Cara Bess [2 ]
Clark, Andrew David [3 ]
Prieto, Elise [2 ]
Waight, Eufemia [4 ]
Largaespada, Natalia [4 ]
机构
[1] Stapleton Lane Clin, Stapleton Lane,POB 8 St Johns, St Johns, Antigua & Barbu
[2] Pan Amer Hlth Org, Washington, DC USA
[3] London Sch Hyg & Trop Med, London WC1, England
[4] Minist Hlth, Belmopan, Belize
关键词
HPV vaccines; Belize; Cervical cancer; Cost-effectiveness;
D O I
10.1016/j.vaccine.2014.12.042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Among women in Belize, cervical cancer is both the leading cancer and the leading cause of cancer deaths. Both the quadrivalent and bivalent human papillomavirus (HPV) vaccines are licensed in Belize. The Ministry of Health of Belize convened a multidisciplinary team to estimate the costs, health benefits, and cost-effectiveness of adding an HPV vaccine to the national immunization schedule. Methodology: The CERVIVAC cost-effectiveness model (Version 1.123) was used to assess the lifetime health and economic outcomes of vaccinating one cohort of girls aged 10 years against HPV. The comparator was no HPV vaccination. The PAHO Revolving Fund negotiated price of US$ 13.79 per dose was used (for the quadrivalent vaccine) and national data sources were used to define demography, cervical cancer incidence and mortality, cervical cancer treatment costs, and vaccine delivery costs. Estimates from international agencies were used in scenario analysis. Results: In a cohort of similar to 4000 Belizean girls tracked over a lifetime, HPV vaccination is estimated to prevent 69 new cases of cervical cancer (undiscounted), and 51 cervical cancer deaths (undiscounted). Considering the potential cervical cancer treatment costs and lost wages avoided by households (societal perspective), the cost per disability-adjusted life year (DALY) averted was estimated to be US$ 429. This increased to US$ 1320 when cervical cancer treatment costs and lost wages were excluded from the analysis. Both estimates are far below the gross domestic product (GDP) per capita of Belize (US$ 4795). The lifetime health care costs saved by the women and their families represent more than 60% of the investment cost needed by the Government for the vaccine. Conclusion: Routine HPV vaccination would be highly cost-effective in Belize. If affordable, efforts should be made to expedite the introduction of this vaccine into the Belizean national immunization program. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:A174 / A181
页数:8
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA
    Obradovic, M.
    Mrhar, A.
    Kos, M.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A272 - A272
  • [2] COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND
    Vaananen, J. J. P.
    Herse, F.
    Korkeamaki, J.
    Parvinen, P. M. T.
    Remy, O.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A431 - A431
  • [3] Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
    Palmer, Cody
    Dolk, Christiaan
    Sabale, Ugne
    Wang, Wei
    Saxena, Kunal
    [J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 312 - 323
  • [4] Cost-effectiveness of HPV 16, 18 vaccination in Brazil
    Goldie, Sue J.
    Kim, Jane J.
    Kobus, Katie
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua
    O'Shea, Meredith K. H.
    Xavier Bosch, F.
    de Sanjose, Silvia
    Franco, Eduardo L.
    [J]. VACCINE, 2007, 25 (33) : 6257 - 6270
  • [5] The cost-effectiveness of male HPV vaccination in the United States
    Chesson, Harrell W.
    Ekwueme, Donatus U.
    Saraiya, Mona
    Dunne, Eileen F.
    Markowitz, Lauri E.
    [J]. VACCINE, 2011, 29 (46) : 8443 - 8450
  • [6] COST-EFFECTIVENESS OF INTERVENTIONS TO INCREASE HPV VACCINATION COVERAGE
    Spencer, Jennifer
    Brewer, Noel T.
    Trogdon, Justin
    Coyne-Beasley, Tamera
    Wheeler, Stephanie B.
    [J]. MEDICAL DECISION MAKING, 2020, 40 (01) : E30 - E31
  • [7] The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective
    Setiawan, Didik
    Luttjeboer, Jos
    Westra, Tjalke Arend
    Wilschut, Jan C.
    Suwantika, Auliya A.
    Daemen, Toos
    Atthobari, Jarir
    Wilffert, Bob
    Postma, Maarten J.
    [J]. EXPERT REVIEW OF VACCINES, 2015, 14 (04) : 589 - 604
  • [8] The potential cost-effectiveness of HPV vaccination among girls in Mongolia
    Luvsan, Munkh-Erdene
    Vodicka, Elisabeth
    Jugder, Uranbolor
    Tudev, Undarmaa
    Clark, Andy
    Groman, Devin
    Otgonbayar, Dashpagam
    Demberelsuren, Sodbayar
    LaMongtagne, D. Scott
    Pecenka, Clint
    [J]. VACCINE: X, 2022, 11
  • [9] BEYOND CERVICAL CANCER: THE COST-EFFECTIVENESS OF HPV VACCINATION IN THE NETHERLANDS
    Setiawan, D.
    Cao, Q.
    Westra, T. A.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A416 - A417
  • [10] Cost-effectiveness of extending the HPV vaccination to boys: a systematic review
    Linertova, Renata
    Guirado-Fuentes, Carmen
    Mar Medina, Javier
    Imaz-Iglesia, Inaki
    Rodriguez-Rodriguez, Leticia
    Carmona-Rodriguez, Montserrat
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2021, 75 (09): : 910 - 916